Jonathan T. Busada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jonathan T. Busada has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin C. Duncan
Department of Microbiology, Immunology, and Cell Biology, West Virginia University School of Medicine, Morgantown, West Virginia
23 shared publications - Gangqing Hu
Department of Microbiology, Immunology & Cell Biology, West Virginia University, Morgantown, West Virginia
22 shared publications Carly J. Amato
21 shared publications- Jennifer Franko
Department of Microbiology, Immunology, and Cell Biology, West Virginia University School of Medicine, Morgantown, West Virginia
21 shared publications - Lei Wang
Department of Microbiology, Immunology, and Cell Biology, West Virginia University School of Medicine, Morgantown, West Virginia
21 shared publications - Quinn Hopen
Department of Microbiology, Immunology, and Cell Biology, West Virginia University School of Medicine, Morgantown, West Virginia
21 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Androgen-Mediated T-cell Suppression Drives Sex Bias in Head and Neck Squamous Cell Carcinoma
Confirmation of sex biases in preclinical HNSCC models. A, Disease-free survival in male and female C57BL/6J mice following 4-NQO exposure, measured as the time to first detectable lesion, and (B) the number of 4-NQO–induced lesions per mouse were assessed weekly. C, 4-NQO–induced lesion area measured at 22 weeks. D, Male and female MOC1 tumor volumes in sham-operated and GDX mice, 6 weeks after tumor induction. E, Overall survival of MOC1 tumor-bearing sham and GDX males. A, B, and E,n ≥ 9 mice per group. For C and D, data are presented as the mean ± SEM with each data point representing an individual mouse. Data are representative of ≥2 independent experiments. Statistical analyses by the (A and E) log-rank test, (B and C) unpaired t test, or (D) two-way ANOVA followed by the Tukey multiple comparisons test. *, P < 0.05; **, P < 0.01.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Androgen-Mediated T-cell Suppression Drives Sex Bias in Head and Neck Squamous Cell Carcinoma
Confirmation of sex biases in preclinical HNSCC models. A, Disease-free survival in male and female C57BL/6J mice following 4-NQO exposure, measured as the time to first detectable lesion, and (B) the number of 4-NQO–induced lesions per mouse were assessed weekly. C, 4-NQO–induced lesion area measured at 22 weeks. D, Male and female MOC1 tumor volumes in sham-operated and GDX mice, 6 weeks after tumor induction. E, Overall survival of MOC1 tumor-bearing sham and GDX males. A, B, and E,n ≥ 9 mice per group. For C and D, data are presented as the mean ± SEM with each data point representing an individual mouse. Data are representative of ≥2 independent experiments. Statistical analyses by the (A and E) log-rank test, (B and C) unpaired t test, or (D) two-way ANOVA followed by the Tukey multiple comparisons test. *, P < 0.05; **, P < 0.01.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Androgen-Mediated T-cell Suppression Drives Sex Bias in Head and Neck Squamous Cell Carcinoma
Sex hormones are the dominant sex determinant driving HNSCC sex biases. A, Schematic overview of the FCG mouse model, illustrating the dissociation of the sex chromosome complement from gonadal sex, with corresponding figure color coding. B, Lesion-free survival, (C) mean time to first lesion, (D) average number of 4-NQO–induced lesions per mouse, and (E) the mean lesion area of 4-NQO–induced lesions were assessed in FCG mice weekly as indicated or at 22 weeks. H, MOC1 tumor volumes were assessed in FCG mice 5 weeks after tumor induction. F, G, and I, The main effects of sex chromosome complement and gonadal sex on the variables assessed in C, E, and H, respectively, are presented by graphing the least squares means of each variable. B and D,n ≥ 9 mice per group. C, E, and H, Data are presented as the mean ± SEM with each data point representing an individual mouse. Data are representative of ≥2 independent experiments. Statistical analyses by the (B) log-rank test followed by the Holm–Šidák multiple comparisons test or (C–E and H) two-way ANOVA followed by the Tukey multiple comparisons tests. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Androgen-Mediated T-cell Suppression Drives Sex Bias in Head and Neck Squamous Cell Carcinoma
Sex hormones are the dominant sex determinant driving HNSCC sex biases. A, Schematic overview of the FCG mouse model, illustrating the dissociation of the sex chromosome complement from gonadal sex, with corresponding figure color coding. B, Lesion-free survival, (C) mean time to first lesion, (D) average number of 4-NQO–induced lesions per mouse, and (E) the mean lesion area of 4-NQO–induced lesions were assessed in FCG mice weekly as indicated or at 22 weeks. H, MOC1 tumor volumes were assessed in FCG mice 5 weeks after tumor induction. F, G, and I, The main effects of sex chromosome complement and gonadal sex on the variables assessed in C, E, and H, respectively, are presented by graphing the least squares means of each variable. B and D,n ≥ 9 mice per group. C, E, and H, Data are presented as the mean ± SEM with each data point representing an individual mouse. Data are representative of ≥2 independent experiments. Statistical analyses by the (B) log-rank test followed by the Holm–Šidák multiple comparisons test or (C–E and H) two-way ANOVA followed by the Tukey multiple comparisons tests. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Data from Androgen-Mediated T-cell Suppression Drives Sex Bias in Head and Neck Squamous Cell Carcinoma
Head and neck squamous cell carcinoma (HNSCC) exhibits a strong sex bias. However, the mechanisms underlying this disparity remain unclear. Using the four core genotypes (FCG) mouse model to uncouple gonadal sex from sex chromosome complement influences, we investigated the contributions of sex hormones and sex chromosomes to HNSCC development and antitumor immunity. Male-biased tumor growth was confirmed in 4-nitroquinoline-1-oxide (4-NQO)–induced oral lesions and orthotopic MOC1 tumors in both wild-type (WT) and FCG mice. Gonadal sex, rather than sex chromosomes, was identified as a primary driver of male tumor growth. However, the interactive effects of gonadal sex and possession of an XX chromosome complement limited MOC1 tumor growth in FCG females. Mechanistically, in vitro dihydrotestosterone (DHT) exposure did not increase MOC1 proliferation and induced only modest transcriptomic changes, suggesting that tumor-extrinsic androgen receptor (AR) signaling promotes male tumor growth in vivo. Notably, sex differences in MOC1 tumor growth were eliminated in T-cell receptor α–knockout (TCRαKO) mice, implicating sex-specific T-cell regulation in HNSCC sex biases. Interestingly, castration reduced MOC1 tumor burden and enhanced both T-cell activation and infiltration into male MOC1 tumors, whereas greater CD8+ T-cell responses in XX-possessing FCG females were suggestive of the interactive influence of sex chromosomes and sex hormones on female antitumor immunity. Together, these results identify sex-specific T-cell regulation as a critical factor in HNSCC risk and highlight androgens as a potential therapeutic target to enhance tumor-specific immunity and immunotherapeutic efficacy in patients with HNSCC. Significance:Sex-specific antitumor T-cell immunity is identified as a key promoter of HNSCC sex biases, providing a promising therapeutic target to enhance the immunotherapeutic efficacy in patients with HNSCC.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Androgen-Mediated T-cell Suppression Drives Sex Bias in Head and Neck Squamous Cell Carcinoma
Head and neck squamous cell carcinoma (HNSCC) exhibits a strong sex bias. However, the mechanisms underlying this disparity remain unclear. Using the four core genotypes (FCG) mouse model to uncouple gonadal sex from sex chromosome complement influences, we investigated the contributions of sex hormones and sex chromosomes to HNSCC development and antitumor immunity. Male-biased tumor growth was confirmed in 4-nitroquinoline-1-oxide (4-NQO)–induced oral lesions and orthotopic MOC1 tumors in both wild-type (WT) and FCG mice. Gonadal sex, rather than sex chromosomes, was identified as a primary driver of male tumor growth. However, the interactive effects of gonadal sex and possession of an XX chromosome complement limited MOC1 tumor growth in FCG females. Mechanistically, in vitro dihydrotestosterone (DHT) exposure did not increase MOC1 proliferation and induced only modest transcriptomic changes, suggesting that tumor-extrinsic androgen receptor (AR) signaling promotes male tumor growth in vivo. Notably, sex differences in MOC1 tumor growth were eliminated in T-cell receptor α–knockout (TCRαKO) mice, implicating sex-specific T-cell regulation in HNSCC sex biases. Interestingly, castration reduced MOC1 tumor burden and enhanced both T-cell activation and infiltration into male MOC1 tumors, whereas greater CD8+ T-cell responses in XX-possessing FCG females were suggestive of the interactive influence of sex chromosomes and sex hormones on female antitumor immunity. Together, these results identify sex-specific T-cell regulation as a critical factor in HNSCC risk and highlight androgens as a potential therapeutic target to enhance tumor-specific immunity and immunotherapeutic efficacy in patients with HNSCC. Significance:Sex-specific antitumor T-cell immunity is identified as a key promoter of HNSCC sex biases, providing a promising therapeutic target to enhance the immunotherapeutic efficacy in patients with HNSCC.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from Androgen-Mediated T-cell Suppression Drives Sex Bias in Head and Neck Squamous Cell Carcinoma
AR signaling has minimal impact on MOC1 proliferation or gene expression. A, AR expression was assessed by immunohistochemistry in serially sectioned MOC1 tumors (n = 3) collected at 8 to 10 weeks after tumor induction and (B) quantified. Testes served as the positive control for AR expression. C, Representative immunofluorescence images demonstrating AR nuclear translocation in MOC1 cells following in vitro DHT (100 nmol/L, 3 hours) or vehicle control exposure. D, Quantification is shown as the ratio of nuclear-to-cytoplasmic fluorescence intensity of AR staining in vehicle- versus DHT-treated cells. E, MOC1 cell proliferation in response to DHT (100 nmol/L) was assessed using the CCK-8 assay at the indicated time points. F, Volcano plot illustrating differential gene expression in DHT-treated (100 nmol/L, 6 hours) versus control MOC1 cells, using thresholds of log2 fold change > 0.585 and FDR < 0.05 (n = 5). The identified genes were significantly upregulated (right, red) or downregulated (left, blue) in the DHT-treated group. G, Bubble plot depicting gene sets enriched in DHT-exposed (100 nmol/L, 6 hours) MOC1 cells as assessed by GSEA. NES, normalized enrichment score. Data in B, D, and E are presented as the mean ± SEM and are representative of ≥3 independent experiments. Statistical analyses by the unpaired t test. ****, P < 0.0001. ⍺AR, anti-androgen receptor antibody; OD, optical density.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Androgen-Mediated T-cell Suppression Drives Sex Bias in Head and Neck Squamous Cell Carcinoma
AR signaling has minimal impact on MOC1 proliferation or gene expression. A, AR expression was assessed by immunohistochemistry in serially sectioned MOC1 tumors (n = 3) collected at 8 to 10 weeks after tumor induction and (B) quantified. Testes served as the positive control for AR expression. C, Representative immunofluorescence images demonstrating AR nuclear translocation in MOC1 cells following in vitro DHT (100 nmol/L, 3 hours) or vehicle control exposure. D, Quantification is shown as the ratio of nuclear-to-cytoplasmic fluorescence intensity of AR staining in vehicle- versus DHT-treated cells. E, MOC1 cell proliferation in response to DHT (100 nmol/L) was assessed using the CCK-8 assay at the indicated time points. F, Volcano plot illustrating differential gene expression in DHT-treated (100 nmol/L, 6 hours) versus control MOC1 cells, using thresholds of log2 fold change > 0.585 and FDR < 0.05 (n = 5). The identified genes were significantly upregulated (right, red) or downregulated (left, blue) in the DHT-treated group. G, Bubble plot depicting gene sets enriched in DHT-exposed (100 nmol/L, 6 hours) MOC1 cells as assessed by GSEA. NES, normalized enrichment score. Data in B, D, and E are presented as the mean ± SEM and are representative of ≥3 independent experiments. Statistical analyses by the unpaired t test. ****, P < 0.0001. ⍺AR, anti-androgen receptor antibody; OD, optical density.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure 6 from Androgen-Mediated T-cell Suppression Drives Sex Bias in Head and Neck Squamous Cell Carcinoma
Castration enhances antitumor T-cell responses. Immunophenotyping of (A and B) tumor DLNs and (C and D) TILs isolated from sham-operated or castrated male C57BL/6J mice bearing MOC1 tumors 6 weeks after tumor induction. E and F, CD4+ T cells (CD45+CD4+) and (G and H) CD8+ T cells (CD45+CD8a+) infiltrating into MOC1 tumors were further analyzed to assess their activation status. The frequency (%) of CD4+ and CD8+ T cells expressing (E and G) IFN-γ and (F and H) granzyme B (GZMB) and the geometric mean fluorescence intensity (gMFI) were quantified for each marker. Data are represented as the mean ± SEM with each data point representing an individual mouse. Data are representative of ≥2 independent experiments. Statistical analyses by the unpaired t test. *, P < 0.05; **, P < 0.01.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from Androgen-Mediated T-cell Suppression Drives Sex Bias in Head and Neck Squamous Cell Carcinoma
Castration enhances antitumor T-cell responses. Immunophenotyping of (A and B) tumor DLNs and (C and D) TILs isolated from sham-operated or castrated male C57BL/6J mice bearing MOC1 tumors 6 weeks after tumor induction. E and F, CD4+ T cells (CD45+CD4+) and (G and H) CD8+ T cells (CD45+CD8a+) infiltrating into MOC1 tumors were further analyzed to assess their activation status. The frequency (%) of CD4+ and CD8+ T cells expressing (E and G) IFN-γ and (F and H) granzyme B (GZMB) and the geometric mean fluorescence intensity (gMFI) were quantified for each marker. Data are represented as the mean ± SEM with each data point representing an individual mouse. Data are representative of ≥2 independent experiments. Statistical analyses by the unpaired t test. *, P < 0.05; **, P < 0.01.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure 5 from Androgen-Mediated T-cell Suppression Drives Sex Bias in Head and Neck Squamous Cell Carcinoma
Male gonadal sex is associated with antitumor T-cell responses. Immunophenotyping of the (A and C) percent and (B and D) number of cells in (A and B) cervical DLNs and (C and D) MOC1 tumors of FCG mice was assessed by flow cytometry 5 weeks after tumor induction. Data are presented as the mean ± SEM with each data point representing an individual mouse and are representative of ≥2 independent experiments. Statistical analyses by two-way ANOVA followed by the Tukey multiple comparisons tests. *, P < 0.05; **, P < 0.01; ****, P < 0.0001.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Androgen-Mediated T-cell Suppression Drives Sex Bias in Head and Neck Squamous Cell Carcinoma
Male gonadal sex is associated with antitumor T-cell responses. Immunophenotyping of the (A and C) percent and (B and D) number of cells in (A and B) cervical DLNs and (C and D) MOC1 tumors of FCG mice was assessed by flow cytometry 5 weeks after tumor induction. Data are presented as the mean ± SEM with each data point representing an individual mouse and are representative of ≥2 independent experiments. Statistical analyses by two-way ANOVA followed by the Tukey multiple comparisons tests. *, P < 0.05; **, P < 0.01; ****, P < 0.0001.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Androgen-Mediated T-cell Suppression Drives Sex Bias in Head and Neck Squamous Cell Carcinoma
Figure S1. Flow cytometry gating schema for phenotypic analysis experiments.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Androgen-Mediated T-cell Suppression Drives Sex Bias in Head and Neck Squamous Cell Carcinoma
Figure S1. Flow cytometry gating schema for phenotypic analysis experiments.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from Androgen-Mediated T-cell Suppression Drives Sex Bias in Head and Neck Squamous Cell Carcinoma
Sex-biased MOC1 tumor growth is T-cell dependent. A, MOC1 tumor volumes were assessed weekly in wild-type and TCRαKO mice. Immunophenotyping of the number of cells in (B) cervical DLNs and (C) MOC1 tumors of C57BL/6J mice was assessed by flow cytometry 6 weeks after tumor induction. B and C, Data are presented as the mean ± SEM with each data point representing an individual mouse and are representative of ≥2 independent experiments. A,n ≥ 9 mice per group. Statistical analyses by the (A and C) unpaired t test or (B) two-way ANOVA followed by the Tukey multiple comparisons tests. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Androgen-Mediated T-cell Suppression Drives Sex Bias in Head and Neck Squamous Cell Carcinoma
Sex-biased MOC1 tumor growth is T-cell dependent. A, MOC1 tumor volumes were assessed weekly in wild-type and TCRαKO mice. Immunophenotyping of the number of cells in (B) cervical DLNs and (C) MOC1 tumors of C57BL/6J mice was assessed by flow cytometry 6 weeks after tumor induction. B and C, Data are presented as the mean ± SEM with each data point representing an individual mouse and are representative of ≥2 independent experiments. A,n ≥ 9 mice per group. Statistical analyses by the (A and C) unpaired t test or (B) two-way ANOVA followed by the Tukey multiple comparisons tests. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Androgen-Mediated T-cell Suppression Drives Sex Bias in Head and Neck Squamous Cell Carcinoma
Figure S2. MOC1-bearing males demonstrate weaker anti-tumor immune responses.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Androgen-Mediated T-cell Suppression Drives Sex Bias in Head and Neck Squamous Cell Carcinoma
Figure S2. MOC1-bearing males demonstrate weaker anti-tumor immune responses.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Androgen-Mediated T-cell Suppression Drives Sex Bias in Head and Neck Squamous Cell Carcinoma
Figure S3. Main effects of sex chromosome complement and gonadal sex on anti-tumor immunity in MOC1 tumor-bearing FCG mice.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Androgen-Mediated T-cell Suppression Drives Sex Bias in Head and Neck Squamous Cell Carcinoma
Figure S3. Main effects of sex chromosome complement and gonadal sex on anti-tumor immunity in MOC1 tumor-bearing FCG mice.